Member Info for HedgeHogarth

No doubt this post will be history with all the spam from traders.

Note on placing - probably achieved with the least dilution to prior day share price that I have seen in micro caps for ages. FAB placed at an 80% discount

What a load of hogwash today

Bluejay are a micro cap share - they were publicly short of cash and whilst expressed clear commitment to bringing I'm strategic investment, there was no guarantee, particularly on timing.

So a placing is not underhand, criminal or a surprise to anyone. With a raft of ways to benefit from a lower share price, there probably was some of that going on, but it always does and it's part and parcel of the risk and reward ratio here.

The board talks about articulation of the hidden value in the company. The placing, and the placing before that were at a discount. That means people get the shares at a price lower that the perceived market value of the company. The company come out of the end of a placing with cash and a more compelling share price for new investment.

When the timing is right, I have every confidence this will relate to 2p plus very quickly.

It just needs some patience.

GLA

Looks like someone is properly loading up at 0.41ish

Hi Micky. It depends what you mean by burning. It's unlikely their costs have been significantly so far. In theory it is BAU opex, work 8nvestment in CBR tests and potentially some incremental costs associated with the remanufactured lentivirus. So no huge cause for concern.

However, it does increase the time pressure on the business to make further meaningful progress and breakthroughs that add value to the business ahead of any further raises.

Cash burn will increase when they start phase 1 trials.

Their cash should take them comfortably through H1 next year. The challenge is to deep into phase 1 trials ahead of next raise.

I cannot see a raise at these levels.

All IMO

Following the tweet from David Burton (and the Vlad like) it does sound like news is coming soon. How soon, we don't know but there is a good chance we may see an RNS this week I'd have though based on the usually lead time of tweets from TMS.

Alternatively, it may be alluding to another interview with Vlad. Many investors called for more comms and PR from Hemo - so Vlad may take it as an opportunity to expand on the exciting methodolgies and progress

We're getting very close to the half year update as well. So that should offer some additional insight.

I've gone on record with two main expectations for this year:

1. CAR-T update - I'm expecting something before Xmas, hopefully in Oct/Nov with potential great news that CH is lifted

2. CBR Update - Whist Hemo have prioritised CAR-T - I am expecting another update this year on CBR. It is their second priority and incredibly exciting. If it continues to have blockbuster results in the lab it give Hemo lots of options to help fund its development without dilutiing the shareholders.

I'm actually comfortable if my holding is diluted again in the next 12mth - it's something you have to accept with small caps. However, in conjunction with any future placings I want to see some genuine progress on CAR-T and CBR following the successful fund raise in January 2023. £50m and £100m mCap are my short term targets - I'd like to see the first met without further shareholder dilution.

You called it - a very dumb question, a very deliberate one too...

It does not matter how many shares are in circulation - investors should focus on the mCap of the company.

Seemingly, lots of panic in the traders camp. Monday will be an interesting day :-)

The real money that is made when you get in early.

The price of copper should increase significantly with demand increasingly outstripping supply

Don't let the trader throw you off the scent - the mCap down here is very appealing

Exciting Monday awaits....

Many a true word is spoken in jest

Sorry Stu - i missed your response on Ox Bio. Apologies.

Id still like to see 1 example of where an RNS has been issued to say that paperwork has been sent

This is subjective

“In summary, issuers must notify without delay major new developments that may affect their business if the development may lead to a substantial share price movement.”

Hemo have already told us they have solved the single issue.

So whether you like it or not, I don't think submitting the paperwork is any more important that any other step required to address the 1 issue.

The significant thing is the FDA agreeing with Hemo that they have addressed the issue and lift the clinical hold

I have already "Priced In" the fact that Hemo will respond to FDA. So what matters to be is the response of the FDA

Stu - I do not believe you know anymore than i do in respect of the work required by Hemo once in possession of the re-manufactured lentivirus.

There will be some paperwork and some testing - but how much and how long it will take is not something you or I know. Hemo have kept this very secretive and it's market sensitive.

And yes FDA will take up to 30 days to review.

As I have posted before - It's more important to get it right than it is to get it done quickly. But equally, both Hemo, their prospective partner for the trials and the FDA would not want this period to be any longer than it needs to be. It is the patient that is at the heart of all this - Hemo CAR-T has the potential to significantly improve patient outcomes - It is this that aligns all the stakeholders.

Still waiting for Stu to comment on the Oxford Biomedica and why they did not RNS the submission to FDA?

One2One - I have considered the Chinese / US relations in relation to a number of stocks i have owned. I personally do not expect the USA / China piece to get to that stage - both have too much too lose. The reason that Hemo are getting the Lentivirus manufactured in China is though the relationship with Wuxi who have a huge presence in both in Pennsylvania and Massachusetts.

Alle the big Pharmas will have manufacturing inks to China.

If it really did kick off with China and US we'd have more to worry about that the issue you raise. The bottom would drop of the equity market more broadly.

HermanusInclusus - I imagine whoever mentioned it has the same intent as you. Good try

The company only just raised 45 days ago - £1.3m at 1.75p per share and the directors adding another £30k by directors 3 weeks ago at 1.75p (which was a 28% premium to the share price at the time). The company also had £2m at the start if the year in the bank.

Here is also a clear statement from the recent results

In June 2023, the company successfully raised US$1.7million in new equity from new and importantly existing shareholders to further the development of Hammaslahti Cu-Zn-Ag-Au Project instead, following the unforeseen weather conditions that prevented workable access to Kangerluarsuk. These funds will immediately go towards finalising a MRE on Hammaslahti's E-Lode as well as General Corporate purposes.

In recognition that current shareholders have already borne a significant burden of risk in the past, Bluejay is in discussions with two strategic entities with complimentary attributes which we believe have the ability to strengthen both the financial and technical capabilities of the business as we explore and develop our portfolio of projects. This is aimed to both financially derisk the business as well as create a unique and powerful combination of skills.

Sounds a very average solution to me - a far cry from "one line treatment"

This discovery would simply work alongside the current methods - so highly toxic Chemotherapy and / or Radiotherapy still required.

I beg to differ Stu - explain to be the Oxford Biomedia user case???? Even there RNS to communicate the lifting of the clinical hold was only a REACH RNS

Show us an example of a company that has communicated submission of their complete response to the FDA via RNS....

You may be right, It's not a competition . I just shared my opinion which may be wrong

LOL @ scoredagainsteps

Ofcourse you are ramping!

I note that you have also just posted something very similar on the GDR BB

Hopefully they do not need to run three tests - but I'm really not qualified to judge

If we took the analogy of a Radio Controlled Car (CAR-T) and it's battery (Letivirus) it would be very unlikely to need to test the car multiple times if it was simple an issue with the battery.

For the record - I do not think Hemo need to RNS when they submit the Complete Response to FDA. Oxford Biomedica simply RNSd when hold was lifted

Pumpky - I asked this question at the AGM.

CAR-T showed great promise and overtook CDX as a priority. But CDX remains just as promising and it's feasible that if successful, both could play a role in the clinic. If Eli Lilly had played a bigger role in CDX, i imagine CDX would have made it to the clinic sooner.

CAR-T was developed to help de-risk Hemo - i.e. another clinical candidate

With CAR-T now a matter of days or weeks now away from the clinic - it feels like Hemo made a good decision

I can assure you I did not have any shares when Hemo hit 17p Mr India

You are such a clown Mr India - it beggars belief

This morning you suggest that my ten things never happen

And now, perhaps on the eve of getting In Vivo results for CBR you try to siggest i did not expect it

Go back to playschool pal and chat with people of your own intellect

And for the record, Stu has predicted nothing, he merely got wind of whatever was communicated by Hemo in preparation for what sounds like imminent comms. (Based on DB tweet)